New research in @nejmcatalyst shows Risant Health successfully scaling Kaiser Permanente's approach to #ValueBasedCare in multi-payer, multi-provider environments - data shows better outcomes for patients -https://t.co/VpMXqLPEiN
In @Health_Affairs , @KPIHP examines practical policy steps states can take to help grow the mental health workforce and expand access to care. The article explores how states can ease barriers tied to licensure, supervision, & portability while maintaining quality and safety.
With a growing demand for mental health and substance use disorder services, states should think creatively about policies to extend and grow the workforce. | Forefront
Renee Gross, et al. | @aboutKP
https://t.co/2IxCYn1GvH
With a growing demand for mental health and substance use disorder services, states should think creatively about policies to extend and grow the workforce. | Forefront
Renee Gross, et al. | @aboutKP
https://t.co/2IxCYn1GvH
The majority of promotional expenditures are invested in drug samples, one of the industry’s most important marketing tactics. | Forefront
Judy Butler, et al. | @Pharmed_Out + @aboutKP
https://t.co/WBkvVOB6rD
Mental Health America’s 2025 Policy Institute, proudly sponsored by Kaiser Permanente, is October 14, 2025! This year’s theme: Behavioral Health & Technology: Exploring Tech Innovations that Improve Access and Care. Learn more at https://t.co/ZRXKzJ1DWg
Excited to have Dan Gorenstein moderate our forum on prescription drug policy!
Looking to understand what’s happening in prescription drug policy? Explore @tradeoffspod’s in-depth reporting on the forces driving drug prices, and the potential solutions: https://t.co/0I3WFZhaLS
Medicaid is core to Kaiser Permanente’s mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. New issue briefs shed light how we care for our 1.5 million Medicaid members.
https://t.co/XMMAssfCzK
“How are pharmaceutical companies able to rack up so many patents in the first place that extend their monopolies? The only way to address this abuse is to set a higher bar of inventiveness in order to get a patent.”
🗣️ I-MAK CEO @realtahiramin
🔗 https://t.co/VrPrF2ukGe
In a new @Health_Affairs forefront article, experts Anthony Barrueta and Murray Ross share their insights on how changes in the pharmaceutical R&D market have propelled drug prices higher: https://t.co/qSs8sLO3mn
Applications are now open for our Translational Research #Postdoctoral#Fellowship!
To learn more about this great opportunity to conduct research inside the integrated #healthcare delivery system at @KPDOR@kpnorcal, scan the QR code below or go to: https://t.co/74fa53vXst
We were pleased to join experts sharing their insights on @theNASEM new report on health equity at our recent forum. Watch the video to learn more about how we can help improve health equity https://t.co/BVrpmARnto
"It's about driving outcomes and keeping patients in the center. That is where value-based platforms helping to manage transitions in care are critically important in delivering value for patients as a whole.” Nolan Chang, MD at @HLTHEVENT. #HLTH2024#ValueBasedCare
Our integrated care & coverage model is core to everything we do, providing the foundation to manage through industry challenges and headwinds while owning the evolution of our enterprise so we can bring #ValueBasedCare to more people, said Chair and CEO Greg Adams at #HLTH2024.
Check out our new analysis in the Journal, Population Health Equity and Outcomes (a new publication from @AJMC_Journal!) Telehealth Insights from an Integrated Care System https://t.co/4LOwNRVDLv
Join us along with @theNASEM and @KPMedSchool Oct 7th in Pasadena, CA as we discuss findings from NASEM's new report, Unequal Treatment. https://t.co/2OsptXNf1u
Analysis of Kaiser Permanente patients in California found a 33% reduced risk of dying from colon cancer among those completing at least 1 at-home fecal immunochemical test (FIT) screening.
Published @JAMANetworkOpen https://t.co/Xg9hXclc5c
#KPResearch
https://t.co/h7ikobgIsd
“The more that [drug companies] try to engage in this patent gaming strategy, the less they’re investing into actual research and development, and actually into novel innovation.”
Dr. Ramachandran (@reshmagar) reminds of the opportunity costs associated with patent games.